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Abstract
Objectives. Pregnancy in SSc is burdened with an increased risk of obstetric complications. Little is known about the
underlying placental alterations. This study aimed to better understand pathological changes and the role of inflamma-
tion in SSc placentas. Leucocyte infiltration, inflammatory mediators and atypical chemokine receptor 2 (ACKR2) ex-
pression in SSc placentas were compared with those in other rheumatic diseases (ORD) and healthy controls (HC).
Methods. A case–control study was conducted on eight pregnant SSc patients compared with 16 patients with
ORD and 16 HC matched for gestational age. Clinical data were collected. Placentas were obtained for histopatho-
logical analysis and immunohistochemistry (CD3, CD20, CD11c, CD68, ACKR2). Samples from four SSc, eight ORD
and eight HC were analysed by qPCR for ACKR2 expression and by multiplex assay for cytokines, chemokines
and growth factors involved in angiogenesis and inflammation.
Results. The number of placental CD3, CD68 and CD11 cells was significantly higher in patients affected by
rheumatic diseases (SScþORD) compared with HC. Hepatocyte growth factor was significantly increased in the
group of rheumatic diseases patients (SScþORD) compared with HC, while chemokine (C-C motif) ligand 5 (CCL5)
was significantly higher in SSc patients compared with ORD and HC. CCL5 levels directly correlated with the num-
ber of all local inflammatory cells and higher levels were associated with histological villitis.
Conclusions. Inflammatory alterations characterize placentas from rheumatic disease patients and could predis-
pose to obstetric complications in these subjects.
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Introduction
Patients with rheumatic diseases (RD), especially con-
nective tissue diseases, are at increased risk of obstetric
complications and have historically been advised
against pregnancy. In recent years, contraindications
have been revised in light of new knowledge of the
pathogenesis of the complications and of therapies for
their management [1–4].
Rheumatology key messages
. Placental leukocytes are more numerous in rheumatic diseases, with a possible role in obstetric complications.
. HGF placental levels are higher in rheumatic diseases than in controls and may promote placentation.
. CCL5 expression is higher in SSc placentas and this supports its pathogenetic role.
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Most studies examining fetal outcome and placental
changes in RD concern SLE and APS. Preterm birth,
intrauterine growth restriction (IUGR) and preeclampsia
are frequent complications in SLE [5] and are associated
with trophoblast alterations, villitis, vasculopathy and a
high number of inflammatory cells [6, 7]. In APS the
higher risk of abortion, stillbirth, IUGR and preterm birth
[8] is associated with trophoblast alterations, infarction
and a higher number of placental inflammatory cells [9,
10]. In chronic arthritis, a slightly increased risk of spon-
taneous abortion or preterm birth compared with healthy
population has been described and a lot of studies have
been performed with respect to therapy [11], but no
histological analysis of the placenta has been conducted
so far.
An Italian multicentre study showed that women with
SSc have a higher than normal risk of IUGR, preterm
delivery and very low birth weight babies [12]. In a case
series of 13 SSc patients [13], five showed decidual vas-
culopathy, associated with fetal death in four cases. The
vessels had increased number of perivascular macro-
phages, immunoglobulin deposits and CD4 lymphocytes
compared with healthy controls. A study of three cases
[14] described decidual vasculopathy, villous hypovas-
cularity, stromal fibrosis, increased syncytiotrophoblast
knotting and infarcts in the placentas of SSc patients
compared with healthy controls. Immunohistochemical
analysis revealed increased staining for VEGF, VEGF re-
ceptor 2, connective tissue growth factor and a-smooth
muscle actin in myofibroblasts in SSc patients, as signs
of altered vascular remodelling and fibrosis.
We are particularly interested in the role of the atyp-
ical chemokine receptor 2 (ACKR2), which does not sig-
nal in response to chemokines, but internalizes ligand
and targets it for intracellular degradation, acting as a
chemokine ‘scavenger’ [15]. It is highly expressed in
trophoblasts and may be important in reducing the risk
of inflammation-related miscarriage, minimizing inflam-
matory chemokine exchange between mother and fetus
[16]. ACKR2 knock out mice have fetal loss if infused
with antiphospholipid antibodies or lipopolysaccharides
[17]. Furthermore, ACKR2 levels are higher in the periph-
eral blood mononuclear cells (PBMCs) of patients with
SSc compared with healthy controls [18].
The aim of our study was to analyse the histopatho-
logical placental features of a cohort of SSc patients,
with a focus on the role of inflammation in the pathogen-
esis of obstetric complications and to determine
whether placental ACKR2 might have a role in it.
Methods
Patients
Patients attending the Rheumatology Unit of the IRCCS
Policlinico San Matteo’s Foundation in Pavia, Italy, who
fulfilled the 2013 European League Against Rheumatism/
American College of Rheumatology classification criteria
for SSc [19] and who consecutively became pregnant
between 2013 and 2018, were enrolled in this prospect-
ive study. Pregnant patients with other RD (ORD) classi-
fied according to the current classification criteria [20–
23] were enrolled as the first control group and healthy
pregnant women followed at the Gynaecology and
Obstetrics Unit formed the second control group
(healthy controls, HC). Patients for comparison groups
were consecutively enrolled if matched to SSc patients
by age, body mass index and week of delivery, with a
ratio of 1:2:2. Patients were followed up by the same
physicians during pregnancy. Organ involvement was
evaluated according to the presence of signs and symp-
toms of disease at the visits and imaging data.
Pulmonary involvement was recorded if the chest X-ray,
high resolution CT scan of the thorax, pulmonary func-
tion tests or echocardiography had previously given an
indication of interstitial or vasculopathic lung disease.
Laboratory tests, including autoantibodies, were eval-
uated using commercially available kits.
This study was carried out in accordance with the
Declaration of Helsinki. The local ethics committee has
approved the research protocol and all patients pro-
vided their written informed consent to use their placen-
tas in the study.
Macroscopic and histopathological analysis
Placentas were weighed and underwent macroscopic
examination. Full thickness samples were obtained,
fixed in 10% buffered formalin and embedded in paraf-
fin. Sections (3mm) were stained with haematoxylin,
eosin and Masson’s trichrome for histopathological
examination according to the most recent guidelines
[24] by an expert pathologist who was blind to sample
classification.
Immunohistochemistry
Paraffin-embedded full thickness placental samples
were sliced into 3mm sections, dewaxed and heated in
0.01 M pH 6 sodium citrate buffer for antigen retrieval.
After blocking endogenous peroxidase activity and non-
specific binding, the sections were incubated overnight
with the following primary antihuman antibodies: mouse
monoclonal anti-CD3 (F7.2.38, 1:70, Dako, Glostrup,
Denmark), mouse monoclonal anti-CD20 (L26, 1:126,
Dako), mouse monoclonal anti-CD68 (PG-M1, 1:30,
Dako), rabbit monoclonal anti-CD11c (EP1347Y, 1:500,
Abcam, Cambridge, UK) and rabbit polyclonal anti-
ACKR2 (1:400, Sigma-Aldrich, St Louis, MO, USA).
Sections were then incubated with the appropriate
chromogenic secondary antibody (ImmPRESS Polymer
Detection Kit, anti-rabbit and anti-mouse, Vector
Laboratories, Burlingame, CA, USA). The immunoreac-
tivity was developed using 3,30-diaminobenzidine tetra-
hydrochloride (Vector Laboratories) as chromogen.
Isotype-matched control antibodies were included as a
negative control and tonsil sections as a positive con-
trol. The sections were observed under a light micro-
scope (Olympus BX43, Olympus, Tokyo, Japan) and
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photographed by digital camera (DP22 using Olympus
Cell Sense Entry 2.2 for imaging acquisition).
Analysis of immunostaining
The immunostaining for CD3, CD20, CD11c and CD68
was assessed as follow. Photographs were taken of 10
random fields (40 magnification) along the sections
and representative of all placental layers. Stained cells
were counted by two blinded observers and normalized
to the tissue area. The percentage of stained area was
assessed in sections stained for ACKR2 and with
Masson’s thrichrome. ImageJ 2.0 software was used to
measure stained area and total area of tissue repre-
sented in the fields examined.
Real-time quantitative polymerase chain reaction
Random parenchymal biopsies were performed in half
of the samples and stored in RNAlater (Thermo Fisher
Scientific, Waltham, MA, USA) at 80C. To extract
RNA, samples were lysed and homogenized in b-mer-
captoethanol and RLT buffer by shaking with steel
beads in a Tissue Lyser LT (Qiagen, Valencia, CA, USA).
RNA was then extracted and purified from the fluid
phase using the RNeasy Mini extraction kit (Qiagen).
Purified RNA was converted to cDNA using the high
capacity RNA to cDNA kit (Thermo Fisher Scientific).
Samples were tested in triplicate and qPCR for ACKR2
was performed as previously described [25]. ACKR2
transcript levels were normalized to TATA-binding pro-
tein. The samples were run on a QuantStudio 7 flex ma-
chine (Thermo Fisher Scientific).
Protein extraction and multiplex cytokine assay
Placental samples were suspended in tissue extraction
buffer (homemade with 100 mM pH 7.4 Tris, 150 mM
NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5%
sodium deoxycholate and protease inhibitors), homo-
genized and the concentration of total proteins in the
supernatant was determined by Pierce BCA Protein
Assay Kit (Thermo Fisher Scientific). Protein concentra-
tion in the samples was normalized to the sample with
the lowest concentration. Samples were analysed as per
protocol using a 30-Plex bioassay (Thermo Fisher
Scientific) measuring interleukin (IL)-1b, IL-1ra, IL-2, IL-
2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-13,
IL-15, IL-17, TNF-a, IFN-a, IFN-c, GM-CSF, G-CSF, che-
mokine (C-C motif) ligand (CCL)2, CCL3, CCL4, CCL5,
chemokine (C-X-C motif) ligand (CXCL)9, CXCL10,
CCL11, VEGF, fibroblast growth factor, hepatocyte
growth factor (HGF) and epidermal growth factor.
Statistical analysis
For all statistical tests, non-parametric data were ana-
lysed using the Mann–Whitney U-test and parametric
data using Student’s unpaired t-test. For multiple com-
parisons, a Kruskal–Wallis correction was applied to the
test. To detect significant correlation between variables,
Spearman’s correlation coefficient was used, where
r¼1 denotes a perfect positive correlation and r¼1 a
perfect negative correlation. P< 0.05 denotes significant
differences. Comparisons were also made between
each of the following groups: SSc, SLE, UCTD, defined
connective tissue disease (SScþSLEþSjögren’s syn-
drome) patients; SSc patients with obstetric complica-
tions, SSc patients without obstetric complications,
SSCþORD patients with obstetric complications,
SScþORD patients without obstetric complications, HC,
all complicated pregnancies, patients who had pree-
clampsia, patients with poor fetal outcome (IUGR, small
for gestational age, death), patients with preterm birth,
patients with premature rupture of membranes, all non-
complicated pregnancies.
Statistical analyses were performed using Prism 8.0.2
for Macintosh (GraphPad Software Inc., La Jolla, CA,
USA).
Results
Main clinical features of the study patients
A total of eight patients affected by SSc, 16 with ORD
and 16 HC were enrolled in the study. All SSc patients
but one took low dose acetylsalicylic acid during preg-
nancy and one patient took prednisolone 4 mg daily in
addition. Their main clinical and pregnancy-related fea-
tures are shown in Table 1.
The patients affected by ORD included 10 patients
with UCTD, characterized by presence of autoantibodies
and arthritis or cytopenias, none satisfying Very Early
Diagnosis of SSc (VEDOSS) classification criteria, three
with SLE, two with idiopathic juvenile arthritis and one
patient with Sjögren’s syndrome (SjS). Their main clinic-
al and pregnancy-related features are shown in
Supplementary Tables 1 and 2, available at
Rheumatology online.
Macroscopic and histopathological findings
No macroscopic placental differences (dimension,
weight) were observed between groups. At histological
examination, no significant difference (P>0.05) was
found between groups, or between the HC vs the SSc
patients and vs the RD patients (SScþORD) regarding
the presence of deciduitis, villitis, materno-fetal inflam-
mation, placental abruption, vascular alterations or fibrin
deposits. The latter was examined both by histopatho-
logical examination and by Masson’s trichrome staining.
The histopathological data did not show any correlation
or association with disease-related features as disease
subset, disease duration, modified Rodnan skin score
(mRSS) and organ involvement.
Inflammatory cells within placentas
The number of placental CD3 and CD11cþ cells found
by immunohistochemistry was significantly higher in
patients affected by RD (SScþORD) compared with HC.
The SSc group alone did not statistically differ from the
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ORD group nor the HC, possibly due to a smaller sam-
ple size. The number of placental CD68þ cells was sig-
nificantly higher in both the SSc and ORD groups
compared with HC (Fig. 1). Patients with histological evi-
dence of placental abruption had a higher number of
placental CD68þ cells, regardless of diagnosis (Fig. 2).
The number of CD20þ cells was not statistically dif-
ferent between the groups (Supplementary Fig. S1,
available at Rheumatology online), even though there
was a trend towards higher numbers in the SScþORD
group (P¼ 0.058).
Similar results were obtained comparing SSc patients
and HC: CD3þ (P<0.05), CD11cþ (P<0.05) and
CD68þ (P<0.01) cells were significantly higher in the
first group, while CD20þ cell number was not different.
Placental ACKR2 expression and transcription
There was strong staining of ACKR2 in all sections and
there was no difference in the stained area between the
groups (SSc vs ORD vs HC, SSc vs HC, SScþORD vs
HC). Real-time quantitative polymerase chain reaction
(RT-qPCR) analysis showed very high transcript levels in
all groups, without significant differences between them.
Moreover, ACKR2 expression and transcription levels
did not correlate with any clinical (disease subset, dis-
ease duration, mRSS, internal organ involvement) or ob-
stetric variable (presence of complications, week of
delivery, presence of histological alterations as above
detailed).
ACKR2 transcript levels correlated with the percentage
of stained area in immunohistochemistry (Supplementary
Fig. S2, available at Rheumatology online), indicating
concordance with protein expression.
FIG. 1 Immunohistochemical analysis
(A) CD3, CD11c and CD68 expression in placentas from patients with SSc, other rheumatic diseases (ORD) and
healthy controls (HC). Scale bar: 20 lm. (B) Median and 95% CI of CD3þ, CD11cþ and CD68þ cell expression per
mm2 in HC compared with rheumatic disease patients (ORDþSSc). (C) Median and 95% CI of CD3þ, CD11cþ and
CD68þ cell expression per mm2 of HC, ORD and SSc groups. *P <0.05, **P <0.001, ***P <0.0001
FIG. 2 Placental macrophages in relation to placental
abruption
The number of CD68þ cells/mm2 in placentas from
patients with and without placental abruption (pl.
abrupt.). *P <0.05.
https://academic.oup.com/rheumatology 3311
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Inflammatory mediators and growth factors in
placenta
We measured levels of a broad range of inflammatory
mediators and growth factors in the placentas from four
SSc patients (two dc-SSc, two lc-SSc), eight patients
affected by ORD and eight HC. Only those molecules
showing significant differences between groups were
considered in further analyses and in clinical correlates.
Specifically, HGF was significantly increased in RD
patients (SScþORD) compared with HC (P< 0.05) and
CCL5 was significantly higher in SSc patients compared
with ORD (P< 0.05) and with HC (P<0.01) (Fig. 3).
When analysing SSc vs HC group, HGF levels were
not different (P> 0.05), while CCL5 levels were signifi-
cantly higher (P<0.01).
HGF levels inversely correlated with the gestational
week at delivery (Fig. 4A) and when the disease groups
were analysed separately, a significant inverse correl-
ation was seen in the rheumatic disease patients group
(SScþORD), but not in HC (Fig. 4B and C). The same
was detected for placental weight, which inversely cor-
related with HGF in patients affected by RD
(Supplementary Fig. S3, available at Rheumatology on-
line). Accordingly, HGF levels were higher in patients
with preterm delivery, regardless of the diagnosis
(Fig. 4D). Higher levels of placental CCL5 were associ-
ated with histological villitis (Fig. 4E).
No clear associations were seen between HGF, CCL5
and disease-related clinical features (disease subset,
disease duration, mRSS, internal organ involvement),
while direct significant correlation was noted between
CCL5 and the number of all inflammatory cells consid-
ered in immunohistochemistry. Moreover, the number of
CD3þ cells directly correlated with the number of
CD20þ and CD11cþ cells. The number of CD68þ cells
directly correlated with the number of CD11cþ cells and
with decidual HGF levels (see Table 2 for descriptive
statistics presented as r-values).
Comparisons between distinct rheumatic diseases
As the ORD group included heterogeneous RD, we ana-
lysed if any differences in placental leukocytes, inflam-
matory mediators or growth factors, or ACKR2 levels
could be detected among them. In particular, we con-
sidered SSc vs SLE patients, SSc vs UCTD patients,
SLE vs UCTD patients and UCTD vs defined connective
tissue disease (SScþSLEþSjS). CD20þ cells were
higher in placentas from defined connective tissue dis-
eases compared with UCTD (P<0.01). No other signifi-
cant findings were observed between groups, except
from a trend toward higher placental CCL5 levels
(P¼0.06) in SSc compared with UCTD patients.
Comparisons between successful and complicated
pregnancies
We investigated if any distinctive alteration could be
found in patients with obstetric complications.
Therefore, we considered sub-groups of patients and
analysed if differences could be detected in placental
CD3þ, CD20þ, CD11cþ, CD68þ cells, ACKR2 expres-
sion and transcription, inflammatory mediators and
growth factors. No significant findings have been
detected, except from a trend toward higher placental
CD68þ cells (P¼0.07) and HGF (P¼ 0.06) in preterm
placentas and to higher CCL5 in patients with pree-
clampsia (P¼0.07).
Discussion
In this study we analysed how inflammation might play a
role in obstetric complications that frequently occur in
the pregnancies of patients affected by RD, in particular
SSc. To our knowledge, this is the largest cohort thus
far analysed in SSc.
We found that patients with RD had higher numbers
of placental leukocytes, specifically T lymphocytes
(CD3þ cells), antigen-presenting cells (APCs, CD11þ
cells) and macrophages (CD68þ cells), compared with
HC.
Our results are in line with and reinforce previous lit-
erature showing an increased number of placental leu-
kocytes in these patients [6, 7, 9, 10]. This has been
associated with obstetric complications such as IUGR,
preeclampsia, fetal death and preterm delivery [26–28].
Placental macrophage infiltration might play a role in
reducing trophoblastic invasion, in placental abruption
[9, 29] and in preterm labour [30]. In addition, an associ-
ation between high maternal serum and placental con-
centrations of M-CSF with IUGR [31] and preeclampsia
[32] has been reported. Other evidence suggests that
placental T cell infiltration and imbalance are important
in the aetiopathogenesis of preeclampsia [33]. In our
population a higher number of placental macrophages
was associated with placental abruption and a trend to-
wards higher CD68þ cells in preterm placentas was
shown, regardless of diagnosis of rheumatic diseases.
No other significant association was found between
FIG. 3 HGF and CCL5 placental levels
Levels of the hepatocyte growth factor (HGF) and of
chemokine (C-C motif) ligand 5 (CCL5) in healthy con-
trols (HC), patients with other rheumatic diseases (ORD)
and SSc. *P <0.05, **P <0.01, ns: not significant.
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inflammatory cell numbers and obstetric complications,
considering SSc patients, RD patients or all complicated
pregnancies regardless of diagnosis. It is possible that
with our small population we did not have enough
statistical power to detect more subtle differences in
other leucocyte populations among patients with and
without obstetric complications (and in sub-groups of
rheumatic diseases patients). Therefore, we can only
FIG. 4 HGF/CCL5 levels and obstetric complications
(A) Considering all patients, levels of hepatocyte growth factor (HGF) inversely correlated with the gestational week at
delivery (r¼0.47, P< 0.05). (B, C) The inverse correlation is maintained in the rheumatic diseases group [other rheum-
atic diseases (ORD)þSSc; r¼0.5, P< 0.05] (B), but not in the healthy controls (HC) group (P>0.05) (C). (D)
Differences in HGF levels in patients with and without preterm delivery. (E) Chemokine (C-C motif) ligand 5 (CCL5)
levels in patients with and without histological villitis. *P< 0.05, **P< 0.01.
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speculate that SSc patients, and in general RD women,
may be more predisposed to obstetric complications due
to the development of placental inflammatory alterations.
The proangiogenic factor HGF [34] was higher in patients
with RD (SScþORD) compared with HC. In placenta, HGF
is produced by stromal cells of the villous mesenchyme and
stimulates trophoblast invasion in the decidua [35]. Its levels
are reduced in hypoxic conditions and in patients with pree-
clampsia [36]. It might be speculated that patients with RD
need higher levels of HGF to promote trophoblast invasion
and placentation. In support of this, in our population HGF
levels inversely correlated with gestational week and placen-
tal weight in patients with RD but not in controls, suggesting
an important role of this factor in women affected by auto-
immune diseases, with higher levels in early stages when
placenta is still developing and lower values in the end
stages of pregnancy.
An important insight provided by our study concerns
CCL5, which was significantly higher in placenta from
patients with SSc compared with ORD and HC, with no
difference between the latter two groups and which
appeared to be related to villitis and to preeclampsia,
regardless of rheumatic disease, although the latter as-
sociation did not reach full statistical significance. These
may indicate a disease specific role of this chemokine in
SSc. CCL5 mediates trafficking and activation of several
immune cells [37]. An association has been demon-
strated between a specific polymorphism of the gene
coding for CCL5 and susceptibility for SSc [38]. CCL5
has been implicated in the pathogenesis of perivascular
inflammation, vascular dysfunction [39, 40], hepatic and
renal fibrosis [41–43], and myocardial remodelling [44].
Furthermore, CCL5 is highly expressed in the skin of
patients with SSc, while no expression has been found
in the skin of controls [45]. Specifically, CCL5 is highly
expressed in skin in early SSc, as are CCL2, CCL3,
CCL4 and CX3CL1. In advanced stages CCL7 and
CXCL10 predominate [46]. The early expression of
CCL2, CCL3 and CCL5 is also observed in a mouse
model of scleroderma, with a subsequent rapid reduction
of CCL5 and maintained high expression of CCL2 and
CCL3 [47]. Another study showed that CCL2, CCL3 and
CCL5 were significantly higher in serum of patients with
SSc than in controls and therapy with prostaglandins
down-regulated CCL2 and CCL5, suggesting an effect of
vasodilator therapy on inflammation in SSc [48].
Considering the placenta as a new organ, with possible
gradual involvement by the disease, CCL5 could be a
key regulator of the pathological process. Through its
chemoattractive activity it could promote the formation of
a placental inflammatory infiltrate, and in fact in this study
we have shown a correlation between CCL5 levels and
leukocytes infiltration. Moreover, it could be a key factor
in the development of vascular alterations and, in the
subsequent stages, of fibrosis.
We did not find different levels of transcription or ex-
pression of placental ACKR2 in SSc or ORD compared
with HC. In a previous study, ACKR2 levels were higher
in PBMCs of SSc patients compared with controls [18].
Furthermore, ACKR2 was elevated in PBMCs and syn-
ovial tissue of patients with inflammatory arthropathies
[49]. In our population, PBMCs from pregnant patients
were not always available and thus we could not per-
form a group analysis, but it would be interesting in fu-
ture studies to compare PBMCs and placental levels of
ACKR2. A possible explanation for similar ACKR2 levels
in our groups could be that ACKR2 is strongly
expressed in placenta and in our patients its immuno-
modulatory role was sufficient to control the inflamma-
tion induced by the inflammatory cells present in the
tissue. In fact, the number of leukocytes, although
higher in patients with RD, was not associated with ob-
stetric complications, except from placental abruption.
The only ACKR2 ligand found to be elevated was CCL5
in patients with SSc, underlining a prominent activity of
this chemokine in these patients.
In conclusion, there is increased placental leucocyte in-
filtration in patients with RD and this may contribute to the
risk of complications. High HGF levels could represent a
protective mechanism for an adequate placentation. In
SSc, CCL5 might be a key factor, with a role in chemo-
taxis, vascular remodelling and fibrosis development.
This could be considered a pilot study and a larger
population of SSc and RD patients should be enrolled in
order to improve statistical power, perhaps in a multi-
centric study. The detection of defined inflammatory
alterations could help in understanding the pathogenesis
of the poor outcomes affecting SSc and RD pregnan-
cies. Moreover, an analysis of inflammatory features in
relation to therapy could be performed, to detect if low
dose corticosteroids, hydroxychloroquine, other immu-
nosuppressants or anti-platelet agents could have a role
in SSc and RD placental alterations and in specific ob-
stetric complications. In addition, a comparison between
alterations in placental tissue and peripheral blood could
lead to the detection of serum markers predictive of
higher-risk pregnancies, easy to detect at early stages,
when a timely personalized pharmacological intervention
may be performed to prevent complications.
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